Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of...
Samsung Biologics (KRX: 207940.KS) announced that it has reached an agreement with Biogen for the buyout of Biogen's stake in the Samsung Bioepis joint...
